Replies to post #26198 on PharmaCyte Biotech Inc (PMCB)

[pjbwheeeze]

Thank you. I will investigate.

[The Giant]

So, what you are saying is that there is validation for a cell-in-a-box type product because another company is also testing its viability via clinical trials? You could argue that you need to be first to market in biopharma, but there is no guarantee the competitive offering is as effective or will receive approval (same with NVLX). Just because a competitor exists is by no means a bad thing...market validation is important. You just need to back the right horse and I'm backing NVLX.

[Hotelier51]

That's a Great Example of a Real Company.

They have REAL money. Probably close to $100 million dollars, from what I can see. They have BIG TIME investment backing. MAJOR partners.

They have a crack management and scientific team. Look at their CEO and Chairman and compare to Nuvilex. The gulf is laughable.

They are working on cutting edge stem cell therapies.

They are private...ie they aren't wasting time peddling penny stock. They don't have to.

Nuvilex on the other hand is a five year old company with zero revenues, zero human trials, zero large investors, a management full of associations to penny stock bloodbaths and other fruitless ventures. And they awarded themselves with over $14 million in insider stock compensation,over 80% of company expenses, while diluting your shares. Further harming the value of your shares via material deception, all while holding licenses to two patents that date back to 1990's and are associated with Austrianova, a company that already tried to advance this product a dozen years ago, which lead to nothing but their own bankruptcy.

Diabetes would be better off if everyone donated to a venture like Viacyte, instead of playing this casino where the house always wins.